IP Library Patent Application 16150254
Patent Application
App. No. 16/150,254

Methods for Improving Drug Treatments in Mammals

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
16/150,254
Abstract

An improved method for identifying the size, shape and duration of drug exposure necessary to improve drug treatment in a subject with a bacterial infection. In addition, an improved method for identification of new dosing strategies which optimize the probability of positive treatment outcomes in subjects using resistance inhibitory concentration (RIC), wherein the subject has a bacterial infection caused by a bacterium with a propensity for heteroresistance. Further, an improved method for decreasing the potential for on-therapy drug resistance by determining a patient's RIC prior to administration of fosfomycin treatment, wherein RIC is utilized to differentiate the parameter which is best related to the driver or index of fosfomycin efficacy for the resistant subpopulation present and the required inhibitory concentration of those mutants.

Claims (1)

1 . A method for treating a subject with a bacterial infection that includes infection with a “resistant” mutant subpopulation of E. coli, the method comprising administering fosfomycin to a subject according to an optimum dosing interval consistent with the resistance inhibitory concentration (RIC) of fosfomycin required to inhibit the “resistant” mutant subpopulations of E. coli, wherein bacterial density is effectively reduced and the “resistant” mutant subpopulation is inhibited.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Jul 20, 2023
From: HERCULES CAPITAL, INC.
To: ZAVANTE THERAPEUTICS, INC.
Reel/Frame 064327/0116 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 17, 2020
From: NABRIVA THERAPEUTICS IRELAND DAC
To: ZAVANTE THERAPEUTICS, INC.
Reel/Frame 054685/0765 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 7, 2020
From: ZAVANTE THERAPEUTICS, INC.
To: NABRIVA THERAPEUTICS IRELAND DAC
Reel/Frame 052594/0068 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 8, 2019
From: ELLIS-GROSSE, EVELYN J.; AMBROSE, PAUL G.
To: ZAVANTE THERAPEUTICS, INC.
Reel/Frame 050005/0963 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Dec 20, 2018
From: ZAVANTE THERAPEUTICS, INC
To: HERCULES CAPITAL, INC.
Reel/Frame 047973/0152 →